
Year Ended December 31,	Operating Leases
2026 (excluding the six months ended June 30, 2026)	$	7,599
2027	17,016
2028	16,371
2029	14,776
2030	9,827
Thereafter	29,449
Total lease payments	$	95,038
Less: imputed interest	(16,242)
Present value of operating lease liabilities	$	78,796
Operating lease liabilities, current	$	12,015
Operating lease liabilities, noncurrent	66,781
Total operating lease liabilities	$	78,796

The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes, commercial disputes, competition and other matters, and the Company may become subject to additional types of lawsuits, claims, arbitration proceedings, administrative actions, government investigations and legal and regulatory proceedings in the future. As of June 30, 2026, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.

In August 2022, the Company filed suit against Parse Biosciences, Inc. (“Parse”) in the U.S. District Court for the District of Delaware alleging that Parse’s Evercode Whole Transcriptomics products and ATAC-seq products infringe U.S. Patent Nos.

10,155,981 (the “981 patent”), 10,697,013 (the “013 patent”), 10,240,197 (the “197 patent”), 10,150,995 (the “995 patent”), 10,619,207 (the “207 patent”) and 10,738,357 (the “357 patent”). In February 2025, the Court entered a consent judgment and permanent injunction against Parse with respect to the 995, 207 and 357 patents relating to ATAC-seq. Parse filed petitions for Inter Partes Review (“IPR”) of the 981, 197 and 013 patents which were found unpatentable by the Patent Trial and Appeal Board in February 2025. The Company strongly disagrees with those decisions and has appealed. Oral arguments in the appeal were heard in June 2026. The District Court case is stayed pending the outcome of the appeals.

In August 2025, the Company acquired Scale Bio. Scale Bio and Parse are parties in a litigation in the U.S. District Court for the District of Delaware in which Scale Bio is asserting that Parse’s Evercode products infringe U.S. Patent Nos. 10,626,442, 10,982,256, 11,512,341 and 11,634,752 (the “752 patent”) and Parse is asserting the Scale Bio’s single cell sequencing products infringe U.S. Patent Nos. 10,900,065, 11,168,355 and 11,427,856 (the “Asserted Parse Patents”). In February 2025, the parties filed a stipulation agreeing that Scale Bio’s High Throughput Assay and methods of using such assays do not infringe the Asserted Parse Patents, and dismissing such claims. In October 2025, the Court entered summary judgment that the 752 patent is invalid. The Company strongly disagrees with this decision and plans to appeal. In November 2025, the Court entered summary judgment that the accused Scale Bio products do not infringe the Asserted Parse Patents, and in June 2026 the Court entered summary judgment that the Asserted Parse Patents are invalid. Additional summary judgment motions are pending. Trial is scheduled for August 2026.

Takara and the Company were previously engaged in litigation in multiple jurisdictions involving Takara’s Seeker and Trekker products. In May 2026, the Company and Takara resolved all outstanding litigation between the two companies. All claims in the litigation have been dismissed with prejudice.

In October 2025, the Company filed suit against Illumina, Inc. (“Illumina”) in the U.S. District Court for the District of Delaware. In a first suit, the Company alleges Illumina’s announced spatial technology program infringes U.S. Patent Nos. 11,008,607, 11,549,138, 12,234,505 and 12,297,487. In a second suit, the Company alleges Illumina’s single cell kits and workflow infringe U.S. Patent Nos. 11,692,214, 11,932,902, 12,275,993, 12,305,239 and 12,416,192. Trial in the first suit is scheduled for January 2028. Trial in the second cell suit is scheduled for April 2028.

In May 2026, the Company filed a suit against Element Biosciences, Inc. (“Element”) in the U.S. District Court for the District of Delaware alleging that the Element Aviti24 device and associated kits and reagents infringe U.S. Patent Nos. 11,021,737, 11,566,276, 11,566,277, and 12,264,358. Element filed a partial motion to dismiss in July 2026 and has not yet answered the Complaint. No schedule has been set.

In May 2026, the Company filed a suit in the Munich Local Division of the UPC alleging that the Element Aviti24 device and associated kits and reagents infringe EP 4249605 and EP 4491741. In July 2026, Element filed an opposition in the European Patent Office challenging the validity of the EP 741 patent.

In August 2026, Spatial Genomics, Inc. (“SG”) and the California Institute of Technology (“Caltech”) filed suit against the Company in the U.S. District Court for the District of Delaware alleging that the Company's Xenium platform infringes U.S. Patent Nos. 10,457,980, 11,473,129, 12,305,224, 12,601,007 and 12,630,868. SG and Caltech seek, among other relief, injunctive relief and unspecified damages (including attorneys' fees) in relation to the Company's making, using, selling, offering to sell, exporting and/or importing into the United States the Xenium platform and associated instruments, reagents, components and services. The Company believes SG and Caltech's claims are meritless and intends to vigorously defend itself.